Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 120 entries
Sorted by: Best Match Show Resources per page
Automated Extraction of Dose/Volume Statistics for Radiotherapy-Treatment-Plan Evaluation in Clinical-Trial Quality Assurance.

Frontiers in oncology

Gong YU, Yu J, Pang D, Zhen H, Galvin J, Xiao Y.
PMID: 26973814
Front Oncol. 2016 Mar 03;6:47. doi: 10.3389/fonc.2016.00047. eCollection 2016.

Radiotherapy clinical-trial quality assurance is a crucial yet challenging process. This note presents a tool that automatically extracts dose/volume statistics for determining dosimetry compliance review with improved efficiency and accuracy. A major objective of this study is to develop...

Cite
Gong YU, Yu J, Pang D, et al. Automated Extraction of Dose/Volume Statistics for Radiotherapy-Treatment-Plan Evaluation in Clinical-Trial Quality Assurance. Front Oncol. 2016;6:47doi: 10.3389/fonc.2016.00047.
Gong, Y. U., Yu, J., Pang, D., Zhen, H., Galvin, J., & Xiao, Y. (2016). Automated Extraction of Dose/Volume Statistics for Radiotherapy-Treatment-Plan Evaluation in Clinical-Trial Quality Assurance. Frontiers in oncology, 647. https://doi.org/10.3389/fonc.2016.00047
Gong, Yutao U T, et al. "Automated Extraction of Dose/Volume Statistics for Radiotherapy-Treatment-Plan Evaluation in Clinical-Trial Quality Assurance." Frontiers in oncology vol. 6 (2016): 47. doi: https://doi.org/10.3389/fonc.2016.00047
Gong YU, Yu J, Pang D, Zhen H, Galvin J, Xiao Y. Automated Extraction of Dose/Volume Statistics for Radiotherapy-Treatment-Plan Evaluation in Clinical-Trial Quality Assurance. Front Oncol. 2016 Mar 03;6:47. doi: 10.3389/fonc.2016.00047. eCollection 2016. PMID: 26973814; PMCID: PMC4776636.
Copy Download .nbib Format: NLM
Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression.

Journal of applied statistics

Crager MR, Tang G.
PMID: 26664111
J Appl Stat. 2014;41(12):2676-2695. doi: 10.1080/02664763.2014.925102. Epub 2014 Jun 09.

We propose a method for assessing an individual patient's risk of a future clinical event using clinical trial or cohort data and Cox proportional hazards regression, combining the information from several studies using meta-analysis techniques. The method combines patient-specific...

Cite
Crager MR, Tang G. Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression. J Appl Stat. 2014;41(12):2676-2695doi: 10.1080/02664763.2014.925102.
Crager, M. R., & Tang, G. (2014). Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression. Journal of applied statistics, 41(12), 2676-2695. https://doi.org/10.1080/02664763.2014.925102
Crager, Michael R, and Tang, Gong. "Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression." Journal of applied statistics vol. 41,12 (2014): 2676-2695. doi: https://doi.org/10.1080/02664763.2014.925102
Crager MR, Tang G. Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression. J Appl Stat. 2014;41(12):2676-2695. doi: 10.1080/02664763.2014.925102. Epub 2014 Jun 09. PMID: 26664111; PMCID: PMC4673004.
Copy Download .nbib Format: NLM
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.

Clinical lung cancer

Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR.
PMID: 33583720
Clin Lung Cancer. 2021 May;22(3):187-194.e1. doi: 10.1016/j.cllc.2021.01.001. Epub 2021 Jan 10.

PURPOSE: This signal finding study (S1400G) was designed to evaluate the efficacy of talazoparib in advanced stage squamous cell lung cancer harboring homologous recombination repair deficiency.PATIENTS AND METHODS: The full eligible population (FEP) had tumors with a deleterious mutation...

Cite
Owonikoko TK, Redman MW, Byers LA, et al. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clin Lung Cancer. 2021;22(3):187-194.e1doi: 10.1016/j.cllc.2021.01.001.
Owonikoko, T. K., Redman, M. W., Byers, L. A., Hirsch, F. R., Mack, P. C., Schwartz, L. H., Bradley, J. D., Stinchcombe, T. E., Leighl, N. B., Al Baghdadi, T., Lara, P., Miao, J., Kelly, K., Ramalingam, S. S., Herbst, R. S., Papadimitrakopoulou, V., & Gandara, D. R. (2021). Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clinical lung cancer, 22(3), 187-194.e1. https://doi.org/10.1016/j.cllc.2021.01.001
Owonikoko, Taofeek K, et al. "Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G." Clinical lung cancer vol. 22,3 (2021): 187-194.e1. doi: https://doi.org/10.1016/j.cllc.2021.01.001
Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clin Lung Cancer. 2021 May;22(3):187-194.e1. doi: 10.1016/j.cllc.2021.01.001. Epub 2021 Jan 10. PMID: 33583720; PMCID: PMC8637652.
Copy Download .nbib Format: NLM
Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients.

Clinical colorectal cancer

Margalit O, Boursi B, Rakez M, Thierry A, Yothers G, Wolmark N, Haller DG, Schmoll HJ, Shi Q, Shacham-Shmueli E, de Gramont A.
PMID: 33775561
Clin Colorectal Cancer. 2021 Jun;20(2):130-136. doi: 10.1016/j.clcc.2021.02.001. Epub 2021 Feb 19.

BACKGROUND: The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) pooled analysis compared 3 to 6 months of adjuvant chemotherapy for stage III colon cancer. Patients were classified into low risk and high risk, suggesting low-risk patients may be offered...

Cite
Margalit O, Boursi B, Rakez M, et al. Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. Clin Colorectal Cancer. 2021;20(2):130-136doi: 10.1016/j.clcc.2021.02.001.
Margalit, O., Boursi, B., Rakez, M., Thierry, A., Yothers, G., Wolmark, N., Haller, D. G., Schmoll, H. J., Shi, Q., Shacham-Shmueli, E., & de Gramont, A. (2021). Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. Clinical colorectal cancer, 20(2), 130-136. https://doi.org/10.1016/j.clcc.2021.02.001
Margalit, Ofer, et al. "Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients." Clinical colorectal cancer vol. 20,2 (2021): 130-136. doi: https://doi.org/10.1016/j.clcc.2021.02.001
Margalit O, Boursi B, Rakez M, Thierry A, Yothers G, Wolmark N, Haller DG, Schmoll HJ, Shi Q, Shacham-Shmueli E, de Gramont A. Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. Clin Colorectal Cancer. 2021 Jun;20(2):130-136. doi: 10.1016/j.clcc.2021.02.001. Epub 2021 Feb 19. PMID: 33775561.
Copy Download .nbib Format: NLM
Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126.

International journal of radiation oncology, biology, physics

Hall WA, Deshmukh S, Bruner DW, Michalski JM, Purdy JA, Bosch W, Bahary JP, Patel MP, Parliament MB, Lock MI, Lau HY, Souhami L, Fisher SA, Kwok Y, Seider MJ, Vigneault E, Rosenthal SA, Gustafson GS, Gay HA, Pugh SL, Sandler HM, Movsas B.
PMID: 34919884
Int J Radiat Oncol Biol Phys. 2022 Jan 01;112(1):83-92. doi: 10.1016/j.ijrobp.2021.07.004.

PURPOSE: External beam radiation therapy (EBRT) dose escalation has been tested in multiple prospective trials. However, the impact on patient reported outcomes (PROs) associated with higher doses of EBRT remain poorly understood. We sought to assess the differences in...

Cite
Hall WA, Deshmukh S, Bruner DW, et al. Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. Int J Radiat Oncol Biol Phys. 2022;112(1):83-92doi: 10.1016/j.ijrobp.2021.07.004.
Hall, W. A., Deshmukh, S., Bruner, D. W., Michalski, J. M., Purdy, J. A., Bosch, W., Bahary, J. P., Patel, M. P., Parliament, M. B., Lock, M. I., Lau, H. Y., Souhami, L., Fisher, S. A., Kwok, Y., Seider, M. J., Vigneault, E., Rosenthal, S. A., Gustafson, G. S., Gay, H. A., Pugh, S. L., Sandler, H. M., & Movsas, B. (2022). Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. International journal of radiation oncology, biology, physics, 112(1), 83-92. https://doi.org/10.1016/j.ijrobp.2021.07.004
Hall, William A, et al. "Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126." International journal of radiation oncology, biology, physics vol. 112,1 (2022): 83-92. doi: https://doi.org/10.1016/j.ijrobp.2021.07.004
Hall WA, Deshmukh S, Bruner DW, Michalski JM, Purdy JA, Bosch W, Bahary JP, Patel MP, Parliament MB, Lock MI, Lau HY, Souhami L, Fisher SA, Kwok Y, Seider MJ, Vigneault E, Rosenthal SA, Gustafson GS, Gay HA, Pugh SL, Sandler HM, Movsas B. Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. Int J Radiat Oncol Biol Phys. 2022 Jan 01;112(1):83-92. doi: 10.1016/j.ijrobp.2021.07.004. PMID: 34919884.
Copy Download .nbib Format: NLM
Use and Perceptions of Opioids Versus Marijuana among Cancer Survivors.

Journal of cancer education : the official journal of the American Association for Cancer Education

Potts JM, Getachew B, Vu M, Nehl E, Yeager KA, Leach CR, Berg CJ.
PMID: 32533537
J Cancer Educ. 2020 Jun 12; doi: 10.1007/s13187-020-01791-5. Epub 2020 Jun 12.

Public health concerns regarding opioids and marijuana have implications for their medical use. This study examined use motives and perceived barriers in relation to opioid and marijuana use and interest in use among US adult cancer survivors. Self-administered surveys...

Cite
Potts JM, Getachew B, Vu M, et al. Use and Perceptions of Opioids Versus Marijuana among Cancer Survivors. J Cancer Educ. 2020;doi: 10.1007/s13187-020-01791-5.
Potts, J. M., Getachew, B., Vu, M., Nehl, E., Yeager, K. A., Leach, C. R., & Berg, C. J. (2020). Use and Perceptions of Opioids Versus Marijuana among Cancer Survivors. Journal of cancer education : the official journal of the American Association for Cancer Education, . https://doi.org/10.1007/s13187-020-01791-5
Potts, Jessica M, et al. "Use and Perceptions of Opioids Versus Marijuana among Cancer Survivors." Journal of cancer education : the official journal of the American Association for Cancer Education vol. (2020). doi: https://doi.org/10.1007/s13187-020-01791-5
Potts JM, Getachew B, Vu M, Nehl E, Yeager KA, Leach CR, Berg CJ. Use and Perceptions of Opioids Versus Marijuana among Cancer Survivors. J Cancer Educ. 2020 Jun 12; doi: 10.1007/s13187-020-01791-5. Epub 2020 Jun 12. PMID: 32533537; PMCID: PMC7736169.
Copy Download .nbib Format: NLM
Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study.

Applied immunohistochemistry & molecular morphology : AIMM

Grushko TA, Filiaci VL, Montag AG, Apushkin M, Gomez MJ, Monovich L, Ramirez NC, Schwab C, Kesterson JP, Seward SM, Method MW, Olopade OI, Fleming GF, Birrer MJ.
PMID: 34224438
Appl Immunohistochem Mol Morphol. 2022 Jan 01;30(1):27-35. doi: 10.1097/PAI.0000000000000949.

We performed a pilot study in anticipation of using long-aged precut formalin-fixed paraffin-embedded tissue sections stored in real-world conditions for translational biomarker studies of topoisomerase 2A (TOP2A), Ki67, and human epidermal growth factor receptor 2 (HER2) in endometrial cancer....

Cite
Grushko TA, Filiaci VL, Montag AG, et al. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022;30(1):27-35doi: 10.1097/PAI.0000000000000949.
Grushko, T. A., Filiaci, V. L., Montag, A. G., Apushkin, M., Gomez, M. J., Monovich, L., Ramirez, N. C., Schwab, C., Kesterson, J. P., Seward, S. M., Method, M. W., Olopade, O. I., Fleming, G. F., & Birrer, M. J. (2022). Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Applied immunohistochemistry & molecular morphology : AIMM, 30(1), 27-35. https://doi.org/10.1097/PAI.0000000000000949
Grushko, Tatyana A, et al. "Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study." Applied immunohistochemistry & molecular morphology : AIMM vol. 30,1 (2022): 27-35. doi: https://doi.org/10.1097/PAI.0000000000000949
Grushko TA, Filiaci VL, Montag AG, Apushkin M, Gomez MJ, Monovich L, Ramirez NC, Schwab C, Kesterson JP, Seward SM, Method MW, Olopade OI, Fleming GF, Birrer MJ. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022 Jan 01;30(1):27-35. doi: 10.1097/PAI.0000000000000949. PMID: 34224438; PMCID: PMC8664981.
Copy Download .nbib Format: NLM
Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522.

Head & neck

Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT.
PMID: 34729846
Head Neck. 2021 Nov 03; doi: 10.1002/hed.26915. Epub 2021 Nov 03.

BACKGROUND: No risk-stratification strategies exist for patients with recurrent oropharyngeal cancer (OPC).METHODS: Retrospective analysis using data from prospective NRG Oncology clinical trials RTOG 0129 and 0522. Eligibility criteria included known p16 status and smoking history, and locoregional/distant recurrence. Overall...

Cite
Bigelow EO, Harris J, Fakhry C, et al. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2021;doi: 10.1002/hed.26915.
Bigelow, E. O., Harris, J., Fakhry, C., Gillison, M. L., Nguyen-Tân, P. F., Rosenthal, D. I., Frank, S. J., Nair, S. G., Bahig, H., Ridge, J. A., Caudell, J., Donaldson, C., Clifford, B. T., Shenouda, G., Birrer, M. J., Chen, Y., & Le, Q. T. (2021). Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head & neck, . https://doi.org/10.1002/hed.26915
Bigelow, Elaine O, et al. "Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522." Head & neck vol. (2021). doi: https://doi.org/10.1002/hed.26915
Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2021 Nov 03; doi: 10.1002/hed.26915. Epub 2021 Nov 03. PMID: 34729846.
Copy Download .nbib Format: NLM
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).

Clinical cancer research : an official journal of the American Association for Cancer Research

Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, Chamberlin MD, Haley BJ, Storniolo AMV, Reddy MP, Anderson SA, Zimmerman CT, O'Dea AP, Mirshahidi HR, Ahnert JR, Brescia FJ, Hahn O, Raymond JM, Biggs DD, Connolly RM, Sharon E, Korde LA, Gray RJ, Mayerson E, Plets M, Blanke CD, Chae YK, Kurzrock R.
PMID: 34716198
Clin Cancer Res. 2021 Oct 29; doi: 10.1158/1078-0432.CCR-21-2182. Epub 2021 Oct 29.

PURPOSE: Metaplastic breast cancer (MpBC) is a rare aggressive subtype that responds poorly to cytotoxics. Median survival is approximately 8 months for metastatic disease. We report results for advanced MpBC treated with ipilimumab + nivolumab, a cohort of S1609...

Cite
Adams S, Othus M, Patel SP, et al. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clin Cancer Res. 2021;doi: 10.1158/1078-0432.CCR-21-2182.
Adams, S., Othus, M., Patel, S. P., Miller, K. D., Chugh, R., Schuetze, S. M., Chamberlin, M. D., Haley, B. J., Storniolo, A. M. V., Reddy, M. P., Anderson, S. A., Zimmerman, C. T., O'Dea, A. P., Mirshahidi, H. R., Ahnert, J. R., Brescia, F. J., Hahn, O., Raymond, J. M., Biggs, D. D., Connolly, R. M., Sharon, E., Korde, L. A., Gray, R. J., Mayerson, E., Plets, M., Blanke, C. D., Chae, Y. K., & Kurzrock, R. (2021). A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clinical cancer research : an official journal of the American Association for Cancer Research, . https://doi.org/10.1158/1078-0432.CCR-21-2182
Adams, Sylvia, et al. "A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)." Clinical cancer research : an official journal of the American Association for Cancer Research vol. (2021). doi: https://doi.org/10.1158/1078-0432.CCR-21-2182
Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, Chamberlin MD, Haley BJ, Storniolo AMV, Reddy MP, Anderson SA, Zimmerman CT, O'Dea AP, Mirshahidi HR, Ahnert JR, Brescia FJ, Hahn O, Raymond JM, Biggs DD, Connolly RM, Sharon E, Korde LA, Gray RJ, Mayerson E, Plets M, Blanke CD, Chae YK, Kurzrock R. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clin Cancer Res. 2021 Oct 29; doi: 10.1158/1078-0432.CCR-21-2182. Epub 2021 Oct 29. PMID: 34716198.
Copy Download .nbib Format: NLM
Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Roncali E, Capala J, Benedict SH, Akabani G, Bednarz B, Bhadrasain V, Bolch WE, Buchsbaum JC, Coleman NC, Dewaraja YK, Frey E, Ghaly M, Grudzinski J, Hobbs RF, Howell RW, Humm JL, Kunos CA, Larson S, Lin FI, Madsen M, Mirzadeh S, Morse D, Pryma D, Sgouros G, St James S, Wahl RL, Xiao Y, Zanzonico P, Zukotynski K.
PMID: 33277396
J Nucl Med. 2021 Aug 01;62(8):1133-1139. doi: 10.2967/jnumed.120.255547. Epub 2020 Dec 04.

In 2018, the National Cancer Institute and NRG Oncology partnered for the first time to host a joint workshop on systemic radiopharmaceutical therapy (RPT) to specifically address dosimetry issues and strategies for future clinical trials. The workshop focused on...

Cite
Roncali E, Capala J, Benedict SH, et al. Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. J Nucl Med. 2020;62(8):1133-1139doi: 10.2967/jnumed.120.255547.
Roncali, E., Capala, J., Benedict, S. H., Akabani, G., Bednarz, B., Bhadrasain, V., Bolch, W. E., Buchsbaum, J. C., Coleman, N. C., Dewaraja, Y. K., Frey, E., Ghaly, M., Grudzinski, J., Hobbs, R. F., Howell, R. W., Humm, J. L., Kunos, C. A., Larson, S., Lin, F. I., Madsen, M., Mirzadeh, S., Morse, D., Pryma, D., Sgouros, G., St James, S., Wahl, R. L., Xiao, Y., Zanzonico, P., & Zukotynski, K. (2021). Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 62(8), 1133-1139. https://doi.org/10.2967/jnumed.120.255547
Roncali, Emilie, et al. "Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy." Journal of nuclear medicine : official publication, Society of Nuclear Medicine vol. 62,8 (2021): 1133-1139. doi: https://doi.org/10.2967/jnumed.120.255547
Roncali E, Capala J, Benedict SH, Akabani G, Bednarz B, Bhadrasain V, Bolch WE, Buchsbaum JC, Coleman NC, Dewaraja YK, Frey E, Ghaly M, Grudzinski J, Hobbs RF, Howell RW, Humm JL, Kunos CA, Larson S, Lin FI, Madsen M, Mirzadeh S, Morse D, Pryma D, Sgouros G, St James S, Wahl RL, Xiao Y, Zanzonico P, Zukotynski K. Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. J Nucl Med. 2021 Aug 01;62(8):1133-1139. doi: 10.2967/jnumed.120.255547. Epub 2020 Dec 04. PMID: 33277396.
Copy Download .nbib Format: NLM
NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer.

Cancers

Bauman JE, Harris J, Uppaluri R, Yao M, Ferris RL, Chen J, Jordan RC, Joshi NP, Jujjuvaparu S, Blakaj DM, Henson C, Sheqwara J, Mell LK, Sen N, Clump DA, Garg MK, Yilmaz E, Torres-Saavedra P, Le QT.
PMID: 34207599
Cancers (Basel). 2021 Jun 09;13(12). doi: 10.3390/cancers13122882.

The anti-PD1 monoclonal antibody pembrolizumab improves survival in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Patients with locoregional, pathologically high-risk HNSCC recur frequently despite adjuvant cisplatin-radiation therapy (CRT). Targeting PD1 may reverse immunosuppression induced by HNSCC and CRT....

Cite
Bauman JE, Harris J, Uppaluri R, et al. NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers (Basel). 2021;13(12)doi: 10.3390/cancers13122882.
Bauman, J. E., Harris, J., Uppaluri, R., Yao, M., Ferris, R. L., Chen, J., Jordan, R. C., Joshi, N. P., Jujjuvaparu, S., Blakaj, D. M., Henson, C., Sheqwara, J., Mell, L. K., Sen, N., Clump, D. A., Garg, M. K., Yilmaz, E., Torres-Saavedra, P., & Le, Q. T. (2021). NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers, 13(12), . https://doi.org/10.3390/cancers13122882
Bauman, Julie E, et al. "NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer." Cancers vol. 13,12 (2021). doi: https://doi.org/10.3390/cancers13122882
Bauman JE, Harris J, Uppaluri R, Yao M, Ferris RL, Chen J, Jordan RC, Joshi NP, Jujjuvaparu S, Blakaj DM, Henson C, Sheqwara J, Mell LK, Sen N, Clump DA, Garg MK, Yilmaz E, Torres-Saavedra P, Le QT. NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers (Basel). 2021 Jun 09;13(12). doi: 10.3390/cancers13122882. PMID: 34207599; PMCID: PMC8230356.
Copy Download .nbib Format: NLM
Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522.

Head & neck

Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT.
PMID: 34729846
Head Neck. 2022 Jan;44(1):158-167. doi: 10.1002/hed.26915. Epub 2021 Nov 03.

BACKGROUND: No risk-stratification strategies exist for patients with recurrent oropharyngeal cancer (OPC).METHODS: Retrospective analysis using data from prospective NRG Oncology clinical trials RTOG 0129 and 0522. Eligibility criteria included known p16 status and smoking history, and locoregional/distant recurrence. Overall...

Cite
Bigelow EO, Harris J, Fakhry C, et al. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2021;44(1):158-167doi: 10.1002/hed.26915.
Bigelow, E. O., Harris, J., Fakhry, C., Gillison, M. L., Nguyen-Tân, P. F., Rosenthal, D. I., Frank, S. J., Nair, S. G., Bahig, H., Ridge, J. A., Caudell, J., Donaldson, C., Clifford, B. T., Shenouda, G., Birrer, M. J., Chen, Y., & Le, Q. T. (2022). Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. Head & neck, 44(1), 158-167. https://doi.org/10.1002/hed.26915
Bigelow, Elaine O, et al. "Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522." Head & neck vol. 44,1 (2022): 158-167. doi: https://doi.org/10.1002/hed.26915
Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2022 Jan;44(1):158-167. doi: 10.1002/hed.26915. Epub 2021 Nov 03. PMID: 34729846.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 120 entries